Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | BHMT | Q93088 | 3/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438551 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL6234510 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL6555262 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL6501684 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL19371196 | 0.88 | ALDH1A1 (0.48) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL7876560 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1KIF11SLC7A5 | |
| SCHEMBL7418366 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1KIF11SLC7A5 | |
| SCHEMBL7184921 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1KIF11SLC7A5 | |
| SCHEMBL436388 | 0.80 | PTGS1 (0.56) | ALDH1A1MAPTPTGS1KIF11SLC7A5 | |
| SCHEMBL21443801 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1KIF11SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281093-A1 | ANTI-INFLAMMATORY COMPOUNDS | C.T.G. PHARMA S.R.L. (IT) | 2009-11-12 | — | — | US | claimed |
| US-20090275539-A1 | Nuclear Transcription Factors Regulators | CTG PHARMA S.R.L. (IT) | 2009-11-05 | — | — | US | claimed |
| US-20090227597-A1 | PYRAZOLOPYRIMIDINONES AS PHOSPHODIESTERASE INHIBITORS | CTG PHARMA S.R.L. (IT) | 2009-09-10 | — | — | US | claimed |
| US-20080207751-A1 | Sulindac Derivatives for Treatment of Cancer | SULFIDRIS S.R.L. (IT) | 2008-08-28 | — | — | US | claimed |
| EP-1904440-A1 | SULINDAC DERIVATIVES FOR TREATMENT OF CANCER | Sulfidris S.r.l. (IT) | 2008-04-02 | — | — | EP | claimed |
| EP-1871360-A1 | NEW ANTI-INFLAMMATORY COMPOUNDS | CTG Pharma S.r.l. (IT) | 2008-01-02 | — | — | EP | claimed |
| WO-2007092284-A2 | LOW DOSE NO DONOR-CONTAINING TRANSDERMAL PATCH | CURE THERAPEUCTICS, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| WO-2006134489-A1 | SULINDAC DERIVATIVES FOR TREATMENT OF CANCER | SULFIDRIS S.R.L. (IT) | 2006-12-21 | — | — | WO | claimed |
| WO-2006111791-A1 | NEW ANTI-INFLAMMATORY COMPOUNDS | CTG PHARMA S.R.L. (IT) | 2006-10-26 | — | — | WO | claimed |
| WO-2006037623-A2 | NEW NUCLEAR TRANSCRIPTION FACTORS REGULATORS | CTG PHARMA S.R.L. (IT) | 2006-04-13 | — | — | WO | claimed |
| EP-1645288-A1 | New nuclear transcription factors regulators | CTG Pharma S.r.l. (IT) | 2006-04-12 | — | — | EP | claimed |
| WO-2006024453-A1 | PYRAZOLOPYRIMIDINONES AS PHOSPHODIESTERASE INHIBITORS | CTG PHARMA S.R.L. (IT) | 2006-03-09 | — | — | WO | claimed |
| EP-1630164-A1 | Pyrazolopyrimidinones as phosphodiesterase inhibitors | Expotrend Company SA (CH) | 2006-03-01 | — | — | EP | claimed |
| US-6743419-B1 | APPLYING TO AREA OF MAMMALIAN SKIN NON-DEPILATORY COMPOSITION INCLUDING HAIR GROWTH REDUCING EFFECTIVE AMOUNT OF SELECTED SULFHYDRYL ACTIVE COMPOUND | THE GILLETTE COMPANY | 2004-06-01 | — | — | US | claimed |
| WO-2003099852-A2 | PEPTIDE DERIVATIZATION PROCESS | RESTORAGEN INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-0675712-B1 | REDUCTION OF HAIR GROWTH EMPLOYING SULFHYDRYL REACTIVE COMPOUNDS | GILLETTE CO (US) | 2001-09-19 | — | — | EP | claimed |
| EP-0531031-B1 | Compositions for use in cancer therapy | HOLT JOHN ALFRED GORTON (AU) | 1995-11-02 | — | — | EP | claimed |
| EP-0531031-A1 | Compositions for use in cancer therapy | Holt, John Alfred Gorton (AU) | 1993-03-10 | — | — | EP | claimed |
| JP-7179336-A | — | — | None | — | — | JP | disclosed |
| US-3992187-A | TO INCREASE YIELD OF SUCROSE | HAWAIIAN SUGAR PLANTERS' ASSOCIATION (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207751-A1 | Sulindac Derivatives for Treatment of Cancer | PTGES3, PTGES2, PTGS1 | ALDH1A1 541/4885MAPT 4690/4885PTGS1 3/4885 |
| US-20090227597-A1 | PYRAZOLOPYRIMIDINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE3B, PDE2A | ALDH1A1 461/4885MAPT 4817/4885PTGS1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.